BALAMINESBalaji Amines Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India and internationally. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. It also provides hotels, restaurants, and hospitality services. The company also exports its products to Europe, the United States, and Japan. Balaji Amines Limited was incorporated in 1988 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on BALAMINES — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 27.2% YoY
- • Profit growth: 97.2% YoY
- • Debt/Equity: 0.06
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 6-month return: +36.8%
Bull case
- • Revenue growth: 27.2% YoY
- • Profit growth: 97.2% YoY
- • Debt/Equity: 0.06
- • Price vs SMA200: above
Bear case
- • ROE: 8.5%
- • ROCE: 9.9%
- • RSI: 33
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • ROE: 8.5%
- • ROCE: 9.9%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹95.21). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.